Yes, I've had those same thoughts as of late. It's definitely frustrating.
I keep assuming that it will come together one of these days. Perhaps I am giving management too much credit, but with the revenue stream they have been able to produce the last several years, they are doing something right, and I can't imagine that they are just going to allow it to languish now.
On another note, it seems like the SFDA needs to get its act together. It appears that a number of Chinese pharma companies have been unable to bring drugs to market as soon as they had had expected. I would really like to see Jiangbo rolling out the new drugs, as well as those from Hongrui.
My fingers are crossed.
News 
Market Data 
Discover 
AI
